Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Age Restriction to Be Updated in the TMPPM for Secukinumab (Cosentyx)

Last updated on

On June 1, 2026, the Texas Medicaid & Healthcare Partnership (TMHP) will update the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook, section 6.112, “Secukinumab (Cosentyx),” to align the age restriction with the restriction on the US Food and Drug Administration (FDA) label.

The age restriction for secukinumab (Cosentyx) (procedure code J3247) will be updated from 2 years of age or older to 18 years of age or older.

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.